Cohen Jeffrey I
Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
J Infect Dis. 2008 Mar 1;197 Suppl 2(Suppl 2):S237-41. doi: 10.1086/522129.
A vaccine to prevent herpes zoster (HZ) in adults > or =60 years of age with healthy immune systems was recently approved by the US Food and Drug Administration. This vaccine is contraindicated in persons with certain immunodeficiency states or who are receiving immunosuppressive therapy. On the basis of studies of the varicella vaccine in healthy and immunosuppressed children and studies of HZ vaccine in healthy adults before its licensure, a series of strategies are proposed for evaluating the live HZ vaccine in immunosuppressed persons. In addition, the use of other vaccines, including heat-inactivated or replication-defective varicella-zoster virus to prevent HZ in immunocompromised persons, is also discussed.
一种用于预防60岁及以上免疫系统健康的成年人带状疱疹(HZ)的疫苗最近获得了美国食品药品监督管理局的批准。这种疫苗在某些免疫缺陷状态的人或正在接受免疫抑制治疗的人身上是禁忌的。基于对健康和免疫抑制儿童的水痘疫苗研究以及HZ疫苗在获批前对健康成年人的研究,提出了一系列用于评估免疫抑制人群中活HZ疫苗的策略。此外,还讨论了使用其他疫苗,包括热灭活或复制缺陷的水痘-带状疱疹病毒来预防免疫功能低下人群的HZ。